Company intelligence / Profile preview

Sinomune Pharmaceutical

Ownership: Private
Development stage: Other

Overview

Sinomune Pharmaceutical has several approved and late-stage products primarily in dermatology and nephrology. Its lead programs include combination topical therapies for psoriasis and acne vulgaris, as well as iron-based phosphate binders for hyperphosphatemia. The company also develops traditional Chinese medicine-derived products targeting autoimmune diseases. Clinical results support efficacy in their approved indications.

Therapeutic areas: DermatologyNephrology
Modalities: Small moleculeBiologic (notably topical formulations and herbal extracts)
Industry: Biotech

Drug pipeline

1 asset

ZYG24002

Partnerships

Aptar Pharma – packaging/device partner for rosacea treatment delivery system

Beyond the preview

Go deeper on Sinomune Pharmaceutical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Sinomune Pharmaceutical.

Explore the full profile